Recruiting EARLY_PHASE1 INTERVENTIONAL 1-arm NCT05087745

A Clinical Study on TIL for the Treatment of Advanced Solid Tumors

A Clinical Study on Tumor Infiltrating Lymphocytes for the Treatment of Advanced Solid Tumors

Sponsor: Shanghai Juncell Therapeutics

Conditions Advanced Solid Tumor Effects of Immunotherapy Treatment Side Effects Tumor Infiltrating Lymphocytes

Interventions Tumor Infiltrating Lymphocytes

Updated 6 times since 2021 Last updated: Apr 16, 2024 Started: Dec 10, 2021 Primary completion: Dec 10, 2024 Completion: Dec 10, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Advanced Solid Tumor and Effects of Immunotherapy and is currently actively recruiting participants. Shanghai Juncell Therapeutics leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting EARLY_PHASE1
May 2024 — Jul 2024 [monthly]

Recruiting EARLY_PHASE1
Jan 2023 — May 2024 [monthly]

Recruiting EARLY_PHASE1
Jul 2022 — Jan 2023 [monthly]

Recruiting EARLY_PHASE1

▶ Show 1 earlier version

Nov 2021 — Jul 2022 [monthly]

Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Juncell Therapeutics
Sir Run Run Shaw Hospital

Data source: Shanghai Juncell Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China